Publication | Open Access

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

Hematological MalignancyOncologyElderly PatientsMedicineAcute Myeloid LeukemiaMixed-phenotype Acute LeukemiaHematologyPharmacotherapyIntensive TreatmentAdult T-cell Leukemia-lymphomaPharmacologyMyeloid Neoplasia